alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>


<ARTICLE> 9
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
REGISTRANT'S BALANCE SHEET AS OF DECEMBER 31, 1996 AND THE STATEMENT OF INCOME
FOR THE TWELVE MONTHS ENDED DECEMBER 31, 1996, AND IS QUALIFIED IN ITS ENTIRETY
BY REFERENCE TO SUCH BALANCE SHEET AND STATEMENT OF INCOME AND THE NOTES
THERETO.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-END>                               DEC-31-1996
<CASH>                                          33,673
<INT-BEARING-DEPOSITS>                           3,957
<FED-FUNDS-SOLD>                                14,900
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                     39,477
<INVESTMENTS-CARRYING>                           5,575
<INVESTMENTS-MARKET>                             5,588
<LOANS>                                        291,766
<ALLOWANCE>                                     (4,744)
<TOTAL-ASSETS>                                 410,505
<DEPOSITS>                                     370,966
<SHORT-TERM>                                         0
<LIABILITIES-OTHER>                              3,149
<LONG-TERM>                                        168
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        15,406
<OTHER-SE>                                      20,816
<TOTAL-LIABILITIES-AND-EQUITY>                 410,505
<INTEREST-LOAN>                                 30,939
<INTEREST-INVEST>                                4,073
<INTEREST-OTHER>                                   135
<INTEREST-TOTAL>                                35,147
<INTEREST-DEPOSIT>                               9,850
<INTEREST-EXPENSE>                               9,869
<INTEREST-INCOME-NET>                           25,278
<LOAN-LOSSES>                                    2,200
<SECURITIES-GAINS>                                   0
<EXPENSE-OTHER>                                 21,700
<INCOME-PRETAX>                                  6,642
<INCOME-PRE-EXTRAORDINARY>                       6,642
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     4,183
<EPS-PRIMARY>                                     0.95
<EPS-DILUTED>                                     0.95
<YIELD-ACTUAL>                                     6.4
<LOANS-NON>                                     11,623
<LOANS-PAST>                                     2,829
<LOANS-TROUBLED>                                 4,787
<LOANS-PROBLEM>                                      0
<ALLOWANCE-OPEN>                                 3,644
<CHARGE-OFFS>                                    1,603
<RECOVERIES>                                       503
<ALLOWANCE-CLOSE>                                4,744
<ALLOWANCE-DOMESTIC>                             4,744
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                              0


</TABLE>
Order issued November 24 , 201 4 

# S

In The 

## Court of Appeals

Fifth District of Texas at Dallas

________________________________________

No. 05

- 1 3

- 0 0 635

- CR

No. 05

- 13

- 01385

- CR

No. 05

- 13

- 01386

- CR

________________________________________

DAARON TAYVON BUYCKS

, Appellant



### V.

THE STATE OF TEXAS

, Appellee



### O R D E R

Before Justices O’Neill, Fillmore, and Brown

Based on the Court’s opinion of this date, we GRANT the August 4, 2014 motions of

Julie Woods for leave to withdraw as appointed counsel on appeal. We DIRECT the Clerk of

the Court to remove Julie Woods as counsel of record for appellant. We DIRECT the Clerk of

the Court to send a copy of this order and all future correspondence to Daaron Tayvon Buycks,

TDCJ No. 1851914

, Bradshaw State Jail, P.O. B ox 9000, Henderson, Texas, 75653

/Michael J. O’Neill/

MICHAEL J. O’NEILL

JUSTICE
EXHIBIT 21
 Name
    
    State or other Jurisdiction of IncorporationRFMD, LLC
    
    North CarolinaRFMD Infrastructure Product Group, Inc.
    
    North CarolinaRFMD WPAN, Inc.
    
    DelawareRF Micro Devices Export, Inc.
    
    BarbadosRF Micro Devices International, Inc.
    
    North CarolinaRF Micro Devices UK Ltd
    
    United KingdomRFMD (UK) Limited
    
    United KingdomRF Micro Devices (Holland) B.V.
    
    The NetherlandsRF Micro Devices (Taiwan) B.V.
    
    The NetherlandsRF Micro Devices, Svenska AB
    
    SwedenRF Micro Devices (Denmark) ApS
    
    DenmarkRF Micro Devices (Finland) Oy
    
    FinlandRF Micro Devices (Korea) YH
    
    KoreaRF Micro Devices (Canada) ULC
    
    CanadaRF Micro Devices (Beijing) Co. Ltd.
    
    Peoples Republic of ChinaRFMD (Shanghai) Technology Company, Ltd.
    
    Peoples Republic of ChinaRF Micro Devices (Hong Kong) Pvt. Limited
    
    Hong KongXemod Incorporated
    
    CaliforniaOlin Acquisition Corporation
    
    DelawareMicro Linear International
    
    DelawareISG Broadband, Inc.
    
    CaliforniaSirenza Microdevices (Canada) Inc.
    
    CanadaPremier Devices  A Sirenza Company
    
    CaliforniaPremier Devices German Holding GmbH
    
    GermanyPremier Devices (Shanghai) Co., Ltd.
    
    ShanghaiRFMD Germany GmbH
    
    GermanyRadio Frequency Micro Devices (India) Private Limited
    
    India
[Federal Register Volume 89, Number 18 (Friday, January 26, 2024)]
[Rules and Regulations]
[Page 5093]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-01491]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary

32 CFR Part 286

[Docket ID: DOD-2019-OS-0069]
RIN 0790-AK54


DoD Freedom of Information Act (FOIA) Program; Amendment; 
Correction

AGENCY: Office of the Assistant to the Secretary of Defense for 
Privacy, Civil Liberties, and Transparency (OATSD(PCLT)), Department of 
Defense (DoD).

ACTION: Final rule; correcting amendment.

-----------------------------------------------------------------------

SUMMARY: The DoD is correcting a final rule that published in the 
Federal Register on December 5, 2023. The rule finalized amendments to 
its Freedom of Information Act (FOIA) regulation to update 
organizational names, add additional FOIA Requester Service Centers, 
and adopt the standards in the Department of Justice's Template for 
Agency FOIA Regulations noting the decision to participate in FOIA 
alternative dispute resolution services is voluntary on the part of the 
requester and DoD.

DATES: This final rule correction is effective January 26, 2024.

FOR FURTHER INFORMATION CONTACT: Toni Fuentes at 571-372-0462.

SUPPLEMENTARY INFORMATION: Subsequent to the publication of the final 
rule on December 5, 2023 (88 FR 84236-84238), it was discovered that 
part of an organization's title was missing in one of the amendments to 
paragraph (a) of Sec.  286.3. This document corrects the Code of 
Federal Regulations to add the missing part of the organization's 
title.

List of Subjects in 32 CFR Part 286

    Freedom of information.

    Accordingly, the Department of Defense amends 32 CFR part 286 by 
making the following correcting amendment:

PART 286--DOD FREEDOM OF INFORMATION ACT (FOIA) PROGRAM

0
1. The authority citation for part 286 continues to read as follows:

    Authority: 5 U.S.C. 552.


Sec.  286.3  [Amended]

0
2. In Sec.  286.3, revise paragraph (a) by adding the word ``Defense'' 
before the words ``Counterintelligence and Security Agency''.

    Dated: January 22, 2024.
Aaron T. Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2024-01491 Filed 1-25-24; 8:45 am]
BILLING CODE 6001-FR-P
EXHIBIT 32.2

CERTIFICATION OF SENIOR VICE PRESIDENT, FINANCE  CALLISTO PHARMACEUTICALS, INC.  FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2009  PURSUANT TO 18 U.S.C. SECTION 1350, AS
ADOPTED  PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I am the Senior Vice President, Finance of Callisto Pharmaceuticals, Inc., a Delaware corporation (the "Company"). I am
delivering this certificate in connection with the Form 10-Q of the Company for the quarter ended September 30, 2009 and filed with the Securities and Exchange Commission
("Form 10-Q").

Pursuant
to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I hereby certify that, to the best of my knowledge, the
Form 10-Q fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and that the information contained in the
Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 16, 2009

/s/ BERNARD F. DENOYER Bernard F. Denoyer Senior Vice President, Finance


---



QuickLinks
<PAGE>   1

                                                                   EXHIBIT 23.1


                       CONSENT OF INDEPENDENT ACCOUNTANTS


We consent to the incorporation by reference in the Registration Statement of
Sunstone Hotel Investors, Inc. on Form S-8 being filed under the Securities Act
of 1933, as amended, of our report dated March 28, 1996 on our audits of the
consolidated financial statements and financial statement schedule of Sunstone
Hotel Investors, Inc. and Sunstone Initial Hotels (the Predecessor), of our
report dated March 22, 1996 on our audit of the financial statements of
Sunstone Hotel Properties, Inc. (the Lessee) appearing in the Annual Report on
Form 10-K, as amended, of Sunstone Hotel Investors, Inc. (the "Company") for
the year ended December 31, 1995, of our report dated January 31, 1996 on our
audit of the combined financial statements of The Cypress Inns, Acquisition
Hotels, appearing in the Company's Current Report on Form 8-K/A filed April 19,
1996, of our report dated June 7, 1996 on our audit of the financial statements
of Renton Joint Venture and of our report dated July 2, 1996 on our audit of
the combined financial statements of Bay City Hospitality, Inc. and Price
Hospitality, Inc. appearing in the Prospectus filed pursuant to Rule 424(b)(4)
on August 8, 1996.


Coopers & Lybrand L.L.P.

Los Angeles, California
October 11, 1996
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
  /s/ HASKELL & WHITE LLP
**EXHIBIT 32.1**

**CERTIFICATION OFCHIEF EXECUTIVE OFFICERCALLISTO PHARMACEUTICALS, INC.FORM 10-Q FOR THE QUARTER ENDED JUNE 30, 2007PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTEDPURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I am the Chief Executive Officer of CallistoPharmaceuticals, Inc., a Delaware corporation (the “Company”). I amdelivering this certificate in connection with the Form 10-Q of theCompany for the quarter ended June 30, 2007 and filed with the Securitiesand Exchange Commission (“Form 10-Q”).

Pursuantto 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of theSarbanes-Oxley Act of 2002, I hereby certify that, to the best of my knowledge,the Form 10-Q fully complies with the requirements of Section 13(a) orSection 15(d) of the Securities Exchange Act of 1934 and that theinformation contained in the Form 10-Q fairly presents, in allmaterial respects, the financial condition and results of operations of theCompany.
| Date: August 14, 2007 |                      |
|----------------------------|---------------------------|
|                       | /s/ GARY S. JACOB         |
|                       | Gary S. Jacob             |
|                       | *Chief Executive Officer* |

 

----
Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED
PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, J. Patrick Lashinsky, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
that the Quarterly Report of ZipRealty, Inc. on Form 10-Q for the three months ended March 31, 2009 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in
such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of ZipRealty, Inc.



|                  |  |  |  |     |  |                          |  |                                      
|----------------- |  |  |  | --- |  | ------------------------ |  | -------------------------------------
|                  |  |  | 
|Date: May 6, 2009 |  |  |  | By: |  | /s/ J. Patrick Lashinsky
|                  |  |  |  |     |  |                          |  | J. Patrick Lashinsky                 
|                  |  |  |  |     |  |                          |  | Chief Executive Officer and President

A signed original of this written statement required by Section 906 has been provided by
ZipRealty, Inc. and will be retained by ZipRealty, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
TS – 10KK7G, Physical and Chemical Properties Worksheet, DSC Trace 

Redacted
NOT FINAL UNTIL TIME EXPIRES TO FILE REHEARING

MOTION AND, IF FILED, DETERMINED

IN THE DISTRICT COURT OF APPEAL

OF FLORIDA

SECOND DISTRICT

MICHAEL LEE JACOBS, )

DOC #T21384, )

)

Appellant, )

)

v. ) Case No. 2D18-966 

)

STATE OF FLORIDA, )

)

Appellee. )

___________________________________)

Opinion filed December 14, 2018.

Appeal pursuant to Fla. R. App. P. 

9.141(b)(2) from the Circuit Court for 

Hillsborough County; Kimberly K. 

Fernandez, Judge.

Michael Lee Jacobs, pro se.

Pamela Jo Bondi, Attorney General, 

Tallahassee, and Johnny T. Salgado, 

Assistant Attorney General, Tampa, for 

Appellee.

PER CURIAM.

Affirmed.

NORTHCUTT, BLACK, and BADALAMENTI, JJ., Concur.
EXHIBIT 32.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Annual Report on Form 10-K of Travis Boats & Motors, Inc.
(the  "Company")  for the year  ended  September  30,  2003,  as filed  with the
Securities and Exchange Commission on the date hereof (the "Report"), I, Mark T.
Walton,  President of the Company,  certify,  to my best  knowledge  and belief,
pursuant  to 18  U.S.C.  ss.  1350,  as  adopted  pursuant  to  ss.  906  of the
Sarbanes-Oxley  Act of  2002,  that:  (1) The  Report  fully  complies  with the
requirements  of Section 13(a) or 15(d) of the  Securities  Exchange Act of 1934
(15 U.S.C.  78m(a) or 78o(d));  and (2) The information  contained in the Report
fairly presents,  in all material respects,  the financial condition and results
of operations of the Company.

/s/ Mark T. Walton
Mark T. Walton, President
January 13, 2004
EXHIBIT 21.1





Registrant had the following significant subsidiaries as of June 26, 2002:





Name

State of Incorporation

Percentage OwnershipKeystone Automotive Industries MN, Inc. (1)

Minnesota

100
%Keystone Automotive Industries FL, Inc. (2)

Florida

100
%Keystone Automotive Industries Resources, Inc. (3)

Delaware

100
%Keystone Automotive Industries TN, Inc. (4)

Tennessee

(5
)


---

|(1) |  | Formerly North Star Plating Company
|--- |  | -----------------------------------

|(2) |  | Formerly Inteuro Parts Distributors, Inc.
|--- |  | -----------------------------------------

|(3) |  | Formerly Republic Automotive Parts, Inc.
|--- |  | ----------------------------------------

|(4) |  | Formerly Fenders & More, Inc.
|--- |  | -----------------------------

|(5) |  | A wholly-owned subsidiary of Keystone Automotive Industries Resources, Inc.
|--- |  | ---------------------------------------------------------------------------
104TH CONGRESS

1ST SESSION S. 184

AN ACT

To establish an Office for Rare Disease Research in the

National Institutes of Health, and for other purposes.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled,

3 SECTION 1. SHORT TITLE.

4 This Act may be cited as the ‘‘Office for Rare Disease

5 Research Act of 1995’’.
2

S 184 ES

1 SEC. 2. ESTABLISHMENT OF OFFICE FOR RARE DISEASE

2 RESEARCH.

3 Part A of title IV of the Public Health Service Act

4 (42 U.S.C. 281 et seq.) is amended by adding at the end

5 thereof the following new section:

6 ‘‘SEC. 404F. OFFICE FOR RARE DISEASE RESEARCH.

7 ‘‘(a) ESTABLISHMENT.—There is established within

8 the Office of the Director of the National Institutes of

9 Health an office to be known as the Office for Rare Dis10 ease Research (in this section referred to as the ‘Office’).

11 The Office shall be headed by a director, who shall be ap12 pointed by the Director of the National Institutes of

13 Health.

14 ‘‘(b) PURPOSE.—The purpose of the Office is to pro15 mote and coordinate the conduct of research on rare dis16 eases through a strategic research plan and to establish

17 and manage a rare disease research clinical database.

18 ‘‘(c) ADVISORY COUNCIL.—The Secretary shall es19 tablish an advisory council for the purpose of providing

20 advice to the director of the Office concerning carrying

21 out the strategic research plan and other duties under this

22 section. Section 222 shall apply to such council to the

23 same extent and in the same manner as such section ap24 plies to committees or councils established under such sec25 tion.
3

S 184 ES

1 ‘‘(d) DUTIES.—In carrying out subsection (b), the di2 rector of the Office shall—

3 ‘‘(1) develop a comprehensive plan for the con4 duct and support of research on rare diseases;

5 ‘‘(2) coordinate and disseminate information

6 among the institutes and the public on rare diseases;

7 ‘‘(3) support research training and encourage

8 the participation of a diversity of individuals in the

9 conduct of rare disease research;

10 ‘‘(4) identify projects or research on rare dis11 eases that should be conducted or supported by the

12 National Institutes of Health;

13 ‘‘(5) develop and maintain a central database

14 on current government sponsored clinical research

15 projects for rare diseases;

16 ‘‘(6) determine the need for registries of re17 search subjects and epidemiological studies of rare

18 disease populations; and

19 ‘‘(7) prepare biennial reports on the activities

20 carried out or to be carried out by the Office and
4

S 184 ES

1 submit such reports to the Secretary and the Con2 gress.’’.

Passed the Senate May 18 (legislative day, May 15),

1995.

Attest:

Secretary.
104TH CONGRESS

1ST SESSION S. 184

AN ACT

To establish an Office for Rare Disease Research in

purposes.the National Institutes of Health, and for other
-79 -78 -77 -76 -75 -74 -73

 38

 39

 40

 41

★

▲

▲

▲

▲

★

▲

▲ ▲

▲

 500

 1000

 1500

 500

18 12 06 00

08/06

NOAA HYSPLIT MODEL

 Backward trajectory ending at 2300 UTC 06 Aug 06

 EDAS Meteorological Data

Source

★ at 39.44 N 77.04 W Meters AGL
EX32.2

Written Statement of the Chief Financial Officer Pursuant to 18 U.S.C.  1350

Solely for the purposes of complying with 18 U.S.C. 1350, I, the undersigned
Principal Financial Officer of McKenzie Bay International, Ltd.  (the
"Company"),  hereby certify, based on  my  knowledge,  that  the Quarterly
Report  on Form 10-QSB of the Company  for  the  quarter ended  June 30, 2004
(the "Report") fully complies  with  the requirements of Section 13(a) of the
Securities Exchange Act  of 1934   and  that  information  contained  in  the
Report  fairly presents,  in all material respects, the financial condition  and
results of operations of the Company.

                            Date: September __, 2004

                             /s/ Gregory N. Bakeman
                             ----------------------
                               Gregory N. Bakeman
                          Principal Financial Officer
SPECIAL POWER OF ATTORNEY

         The  undersigned  constitutes  and  appoints  Jon Ehlinger his true and
lawful   attorney-in-fact   and  agent  with  full  power  of  substitution  and
resubstitution,  for him  and in his  name,  place,  and  stead,  in any and all
capacities,  to sign the Annual  Report on Form 10-K for the  fiscal  year ended
December 31, 2000,  for filing with the  Securities  and Exchange  Commission by
Ugly Duckling  Corporation,  a Delaware  corporation,  together with any and all
amendments  to such Form 10-K,  and to file the same with all exhibits  thereto,
and all  documents in connection  therewith,  with the  Securities  and Exchange
Commission,  granting to such  attorneys-in-fact  and agents,  and each of them,
full  power  and  authority  to do and  perform  each and  every  act and  thing
requisite and  necessary to be done in and about the  premises,  as fully and to
all intents and purposes as he might or could do in person, hereby ratifying and
confirming  all that such  attorneys-in-fact  and agents,  or each of them,  may
lawfully do or cause to be done by virtue hereof.

                                                     DATED:   , 2001


                                                /S/ CHRISTOPHER JENNINGS
                                                --------------------------------
                                                Christopher D. Jennings

<PAGE>



STATE OF _______________ )

                         )

County of ______________ )



         On this ____ day of _________,  2001, before me, the undersigned Notary
Public,  personally  appeared  Christopher  D.  Jennings,  known to me to be the
person whose name is subscribed to the within  instrument and acknowledged  that
he executed the same for the purposes therein contained.

         IN WITNESS WHEREOF, I hereunto set my hand and official seal.



                                                --------------------------------
                                                Notary Public

My commission expires: